Back to Authors

Paul, Pritikanta

https://orcid.org/0000-0001-9842-8803

A5029925686 | I180670191

Mayo Clinic

University of California, San Francisco

Citations 25

Immune‐Driven Expression in Inclusion Body Myositis With T‐Cell Large Granular Lymphocytic Leukemia

Annals of Clinical and Translational Neurology | January 9, 2026 | Volume: 13 | Issue: 6 | Pages: 1196-1205

10.1002/acn3.70301 | PMID 41511789

ABSTRACT Objectives T‐cell large granular lymphocytic leukemia (T‐LGLL), reported in up to 58% of inclusion body myositis (IBM) patients, is a rare leukemia of cytotoxic or less commonly helper T cells. The range of myopathies in T‐LGLL and the impact of coexisting T‐LGLL in IBM are not well understood. Our objectives are to investigate the spectrum of myopathies in patients with T‐LGLL and compare the clinical, serological, pathological, and transcriptomic features of IBM patients with and without T‐LGLL. Methods We reviewed two Mayo Clinic cohorts: (1) T‐LGLL patients evaluated for myopathies (2003–2018), and (2) IBM patients tested for T‐LGLL via T‐cell receptor gene rearrangement or flow cytometry (2016–2022). We also compared transcriptomic profiles of IBM muscle biopsies with and without T‐LGLL. Results Of 447 T‐LGLL patients, 13 (2.9%) had myopathies, IBM being the most common ( n = 7). Of 43 IBM patients, 9 (20.9%) had T‐LGLL, with 5 diagnosed prior to the onset of weakness. Clinical and pathological features were largely similar between IBM patients with and without T‐LGLL, except for milder finger flexor weakness and more frequent neutropenia (55.6% vs. 0%, p < 0.001) in the T‐LGLL group. However, transcriptomic analysis of muscle tissues revealed a more immunologically active profile, with upregulation of T‐cell and macrophage markers, elevated levels of IFN‐γ gene and IFN‐γ–inducible genes, heightened cytokine activity, and enhanced immunoglobulin production in IBM patients with T‐LGLL. Interpretation IBM is the most common myopathy in T‐LGLL patients. While clinico‐sero‐pathological features were largely similar, transcriptomic differences suggest IBM with T‐LGLL may represent a distinct, more immune‐driven subtype.
Compound Muscle Action Potential and Myosin-Loss Pathology in Patients With Critical Illness Myopathy

Neurology | June 13, 2024 | Volume: 103 | Issue: 1 | Pages: No page available

10.1212/wnl.0000000000209496 | PMID 38870464

Compound Muscle Action Potential (CMAP) Duration and Myosin Loss in Patients with Critical Illness Myopathy: Correlation and Prognostication (P1-11.005)

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000205833

Peripheral Nervous System Manifestations of MOG Antibody Associated Disease (P9-14.015)

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000204362

Peripheral nervous system manifestations of MOG antibody associated disease

Annals of Clinical and Translational Neurology | January 18, 2024 | Volume: 11 | Issue: 4 | Pages: 1046-1052

10.1002/acn3.52001 | PMID 38234084

AbstractRecent studies have reported the involvement of peripheral nervous system (PNS) in association with MOG‐IgG, including isolated neuropathies. In this retrospective study we characterized the PNS involvement in MOG antibody associated disease (MOGAD). Six out of 215 MOGAD patients had PNS involvement (all polyradiculopathy) that occurred concurrently with a CNS demyelinating episode. We also demonstrated MOG expression in healthy human controls' proximal nerve root. Nine patients with true‐positive MOG‐IgG1 had PNS involvement temporally unrelated to a CNS demyelinating event. All these patients had an alternate etiology of PNS involvement. Isolated peripheral neuropathy is not a feature of MOGAD, but inflammatory nerve root involvement can occur concurrently with CNS demyelinating events.
A Rare Case of Peripheral Neurolymphomatosis in Cutaneous T-cell Lymphoma (P1.9-040)

Neurology | December 7, 2023 | Volume: 92 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.92.15_supplement.p1.9-040

Neurofascin-155 autoimmunity: clinico-pathological associations and outcomes (4297)

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.4297

Population-Based Epidemiology Study of Paraneoplastic Neurological Syndromes (2892)

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.2892

Chloroquine and Hydroxychloroquine Myopathy: Clinical Spectrum and Treatment Outcomes (2541)

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.2541

Anti-cN1A Antibodies do not Help Characterize sIBM (1256)

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.1256